EchoGo Pro vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

EchoGo Pro

by Ultromics

ElucidVivo A.3

by Elucid

AI Verdict

EchoGo Pro automates stress echocardiography analysis to diagnose coronary artery disease, providing near-instant reports from ultrasound images. In contrast, ElucidVivo A.3 analyzes CT angiography images to quantify arterial plaque composition and stability, assisting in atherosclerosis patient stratification. While both are FDA-cleared AI tools for cardiovascular imaging, they utilize different imaging modalities and focus on distinct aspects of cardiac diagnosis and patient management.

Choose EchoGo Pro if…

Choose EchoGo Pro if your primary need is an AI-powered cloud solution for automating stress echocardiography analysis. This tool is ideal for clinics and hospitals seeking near-instant, accurate reports to improve the diagnosis of coronary artery disease through echocardiograms, enhancing workflow efficiency and diagnostic confidence.

View EchoGo Pro →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require an AI-powered medical image analysis system for quantitative assessment of arterial plaque composition and stability from CT angiography. This solution is best suited for physicians focused on stratifying atherosclerosis patients and optimizing treatment decisions based on detailed visualization and measurement of plaque characteristics.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	EchoGo Pro	ElucidVivo A.3
Pricing	Contact vendor for pricing	Unknown
Deployment	Cloud-based (SaaS)	Cloud and on-premise secure deployment.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoGo Pro

EchoGo Pro (Tool A) is a cloud-based SaaS solution that explicitly states it requires no software installation or extensive training, and offers seamless integration with existing clinical workflows. This indicates a higher degree of out-of-the-box usability and easier adoption compared to ElucidVivo A.3 (Tool B), whose deployment details are less explicit.

Clinical Value

ElucidVivo A.3

While both tools offer significant clinical value, ElucidVivo A.3 (Tool B) provides a deeper, more granular analysis of arterial plaque composition and stability from CT angiography, including the objective quantification of Lipid-Rich Necrotic Core and derivation of fractional flow reserve (FFRct), validated against histology. This offers more profound and predictive clinical insights for atherosclerosis patient stratification and treatment optimization.

Pricing & Value

EchoGo Pro

Both tools require direct vendor contact for pricing, limiting transparency. However, EchoGo Pro (Tool A) explicitly mentions available reimbursement codes for related EchoGo products, which suggests a clearer path to financial viability and value realization for healthcare providers, indicating a more mature understanding of the economic landscape for its offerings.

Enterprise Readiness

EchoGo Pro

EchoGo Pro (Tool A) explicitly declares HIPAA compliance, BAA availability, FDA clearance, and a cloud-native deployment with clear integration capabilities (DICOM, HL7, PACS neutrality). ElucidVivo A.3 (Tool B)'s HIPAA compliance and BAA status are inferred rather than explicitly stated, and its deployment model is less clearly defined, making Tool A appear more robust for enterprise adoption.

Innovation

ElucidVivo A.3

Both tools leverage AI for advanced cardiac imaging analysis. However, ElucidVivo A.3 (Tool B)'s capability to quantitatively analyze detailed plaque composition (e.g., Lipid-Rich Necrotic Core) from CT angiography and derive FFRct, with validation against ground-truth histology, represents a more advanced and innovative approach to understanding atherosclerosis, offering predictive insights into plaque stability and risk stratification.

Support & Docs

EchoGo Pro

Ultromics explicitly mentions and provides access to user manuals (Clinician User Manual, Operator Manual) and customer support for EchoGo Pro (Tool A), outlining its use, integration, and training. For ElucidVivo A.3 (Tool B), specific details on customer support or comprehensive documentation are not readily available in the provided information or web searches.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	EchoGo Pro	ElucidVivo A.3
Product Name	EchoGo Pro	ElucidVivo A.3
Company	Ultromics	Elucid Bioimaging
Primary Focus	Automates stress echocardiography analysis to improve the diagnosis of coronary artery disease.	Provides quantitative analysis of arterial plaque composition and stability from CT angiography.
Key Analysis Type	AI-powered automated echocardiogram analysis; Automated identification of coronary artery disease (CAD).	AI-powered quantitative analysis of arterial plaque; Quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Derives fractional flow reserve (FFRct).
Output/Visualization	Provides near-instant, comprehensive reports.	Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Offers rotatable curved MPR vessel views and cross-sections.
Integration/Compatibility	Vendor-neutral system, compatible with any PACS; Seamless integration with existing clinical workflows (DICOM, HL7).	Integrates with PACS/EMR.

Videos

Demos, reviews, and walkthroughs featuring EchoGo Pro and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What imaging modalities do EchoGo Pro and ElucidVivo A.3 utilize, and for what primary cardiovascular conditions are they intended?

EchoGo Pro analyzes stress echocardiography to improve the diagnosis of coronary artery disease (CAD). ElucidVivo A.3 performs quantitative analysis on CT angiography images to assist in atherosclerosis patient stratification and optimize treatment decisions.

What specific analytical insights or measurements do these AI tools provide to physicians?

EchoGo Pro provides near-instant, comprehensive reports from automated echocardiogram analysis, aiding in the identification of CAD. ElucidVivo A.3 objectively quantifies arterial plaque components like Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, and can derive fractional flow reserve (FFRct).

Are there existing reimbursement codes applicable to the use of these AI solutions?

For Ultromics, reimbursement codes are available for related EchoGo products, such as CPT 0932T for EchoGo Heart Failure and NTAP XXE2X19 for inpatient settings. Elucid's Plaque-IQ coronary plaque analysis has received a new Category I CPT code 75577, effective January 1, 2026, with established payment amounts for imaging centers, physician offices, and hospital outpatient settings. Additionally, a CPT Category III code (0710T-0713T) for lipid-rich necrotic core quantification was instated in December 2021.

How do these tools validate their analytical accuracy or clinical utility?

EchoGo Pro aims to improve diagnostic accuracy and reduce misdiagnosis in CAD, with studies demonstrating improved sensitivity of CAD detection. ElucidVivo A.3's plaque analysis is validated against ground-truth histology, the gold standard for plaque characterization.

What are the key differences in the types of cardiovascular disease each tool is designed to help diagnose or manage?

EchoGo Pro is specifically designed for the diagnosis of coronary artery disease using stress echocardiography. ElucidVivo A.3 focuses on atherosclerosis patient stratification and optimizing treatment decisions through detailed analysis of arterial plaque composition from CT angiography.